Medicare Enrolled
Dr. Hari Kalla, MD
Medical Oncology · Abilene, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Kalla from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kalla? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kalla
Dr. Hari Kalla is a medical oncology in Abilene, TX, with 19 years in practice. Based on federal Medicare data, Dr. Kalla performed 108,466 Medicare services across 5,911 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kalla received a total of $2,626 from 25 pharmaceutical and/or device companies across 37 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kalla is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 8% volume in TX$ $2,626 industry payments
Medicare Practice Summary
Medicare Utilization ↗108,466
Medicare services
Top 8% in TX for medical oncology
5,911
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,709 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 34,680 | $0 | $5 |
| Oxaliplatin chemotherapy injection | 17,300 | $0 | $33 |
| Paclitaxel chemotherapy injection | 8,480 | $0 | $8 |
| Pembrolizumab injection (Keytruda) | 8,200 | $43 | $136 |
| Contrast dye for imaging (iodine-based) | 7,326 | $0 | $3 |
| Iron sucrose injection (Venofer) | 4,700 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia | 4,613 | $2 | $20 |
| Immune globulin infusion (Octagam) | 3,310 | $34 | $233 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 3,000 | $23 | $181 |
| Dexamethasone injection (steroid) | 2,247 | $0 | $1 |
| Blood draw (venipuncture) | 1,233 | $8 | $20 |
| Office visit, established patient (30-39 min) | 1,128 | $89 | $368 |
| Complete blood count (CBC) with differential | 1,072 | $8 | $36 |
| Injection, granisetron hydrochloride, 100 mcg | 1,010 | $0 | $24 |
| Comprehensive metabolic blood panel | 891 | $10 | $64 |
| Injection, fluorouracil, 500 mg | 526 | $2 | $13 |
| Injection, leucovorin calcium, per 50 mg | 500 | $3 | $25 |
| Anti-nausea injection (Aloxi/palonosetron) | 480 | $1 | $114 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 445 | $22 | $157 |
| Office visit, established patient, complex (40-54 min) | 413 | $130 | $496 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 408 | $85 | $1,348 |
| Administration of chemotherapy into vein, 1 hour or less | 383 | $98 | $707 |
| Injection, carboplatin, 50 mg | 249 | $2 | $300 |
| Ferritin level test (iron stores) | 223 | $13 | $60 |
| Administration of chemotherapy into vein, each additional hour | 221 | $21 | $161 |
| Iron level test | 215 | $6 | $27 |
| Iron binding capacity test | 215 | $9 | $35 |
| Carcinoembryonic antigen (cea) protein level | 173 | $19 | $99 |
| Blood creatinine level | 168 | $5 | $31 |
| Urea nitrogen level to assess kidney function, quantitative | 168 | $4 | $24 |
| Albumin (protein) level | 162 | $5 | $28 |
| Bilirubin level, total | 162 | $5 | $23 |
| Calcium level, total | 162 | $5 | $30 |
| Carbon dioxide (bicarbonate) level | 162 | $5 | $24 |
| Blood chloride level | 162 | $4 | $25 |
| Phosphatase (enzyme) level, alkaline | 162 | $5 | $27 |
| Blood potassium level | 162 | $5 | $30 |
| Liver enzyme (sgot), level | 162 | $5 | $33 |
| Liver enzyme (sgpt), level | 162 | $5 | $28 |
| Total protein level, blood | 161 | $4 | $42 |
| Injection, diphenhydramine hcl, up to 50 mg | 158 | $1 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 156 | $47 | $313 |
| Injection of additional new drug or substance into vein | 153 | $12 | $108 |
| Microscopic examination for white blood cells with manual cell count | 133 | $4 | $22 |
| Complete blood count (CBC), automated | 133 | $6 | $34 |
| Drug injection, under skin or into muscle | 126 | $11 | $96 |
| Administration of additional new drug or substance into vein, 1 hour or less | 123 | $48 | $344 |
| Hospital follow-up visit, moderate complexity | 117 | $61 | $247 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 105 | $90 | $657 |
| Reticulated (young) platelet measurement | 104 | $35 | $143 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 99 | $1,107 | $4,802 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 98 | $15 | $100 |
| Lactate dehydrogenase (enzyme) level | 96 | $6 | $31 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 89 | $344 | $1,722 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 84 | $69 | $70 |
| Hospital follow-up visit, high complexity | 76 | $91 | $357 |
| Magnesium level test | 69 | $7 | $29 |
| Irrigation of implanted venous access drug delivery device | 69 | $18 | $114 |
| Administration of additional new drug or substance into vein using push technique | 67 | $42 | $289 |
| Ct scan of chest with contrast | 65 | $48 | $821 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 62 | $20 | $128 |
| Unclassified drugs | 62 | $1 | $8 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 61 | $137 | $3,675 |
| CT scan of abdomen and pelvis with contrast | 59 | $150 | $1,067 |
| Office visit, established patient (20-29 min) | 57 | $67 | $250 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 48 | $124 | $500 |
| Infusion, normal saline solution , 1000 cc | 47 | $2 | $19 |
| New patient office visit, complex (60-74 min) | 41 | $153 | $709 |
| Initial hospital admission, high complexity | 39 | $132 | $694 |
| Red blood count automated, with additional calculations | 36 | $5 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 35 | $15 | $94 |
| Application of on-body injector for under skin injection | 34 | $14 | $96 |
| Infusion into a vein for hydration, each additional hour | 31 | $10 | $75 |
| PSA test (prostate cancer screening) | 28 | $18 | $94 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 26 | $26 | $145 |
| New patient office visit (45-59 min) | 25 | $124 | $565 |
| CT scan of chest, without contrast | 16 | $37 | $686 |
| Ct scan of abdomen and pelvis without contrast | 15 | $76 | $560 |
| Drawing of blood for a medical problem | 15 | $63 | $264 |
| Infusion into a vein for hydration, 31-60 minutes | 13 | $22 | $256 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
35.8% high complexity
55.8% medium
8.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,626
Total received (2018-2024)
Avg $438/year across 6 years
Bottom 43% in TX for medical oncology
25
Companies
37
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,602 (99.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$24 (0.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$491
2023$512
2022$466
2020$33
2019$762
2018$361
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$325
GENZYME CORPORATION
$222
Daiichi Sankyo Inc.
$203
Tempus AI, Inc
$163
AbbVie, Inc.
$160
Puma Biotechnology, Inc.
$119
ImmunoGen, Inc.
$117
Amgen Inc.
$114
Verastem, Inc.
$113
CTI BioPharma Corp.
$108
Sirtex Medical Inc
$108
Seagen Inc.
$107
Kite Pharma, Inc.
$102
Novartis Pharmaceuticals Corporation
$102
Genmab U.S., Inc.
$95
Janssen Biotech, Inc.
$82
Takeda Pharmaceuticals U.S.A., Inc.
$80
Gilead Sciences, Inc.
$71
Janssen Scientific Affairs, LLC
$67
PFIZER INC.
$64
Ipsen Biopharmaceuticals, Inc
$38
Eisai Inc.
$33
Otsuka America Pharmaceutical, Inc.
$15
BeiGene USA, Inc.
$15
Clovis Oncology, Inc.
$4
Top 3 companies account for 28.6% of total payments
Associated products mentioned in payments ›
Copiktra · EMPLICITI · ERLEADA · Elahere · Enhertu · Epkinly · Erleada · JEVTANA · KISQALI · LIBTAYO · LUMAKRAS · Lenvima · MYLOTARG · Mavyret · NUEDEXTA · Nerlynx · ONIVYDE · OPDIVO · REBLOZYL · Rubraca · SARCLISA · SIR-Spheres Microspheres · TALZENNA · TEVIMBRA · TIVDAK · Venclexta · Vonjo · XTANDI · Yescarta · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
4
Per 100K population
2.8
County median income
$66,406
Nearest hospital
OCEANS BEHAVIORAL HOSPITAL OF ABILENE
8.9 mi
8.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kalla is a mixed practice specialist, with above-average Medicare volume (top 8% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kalla experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Kalla performed 34,680 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kalla receive payments from pharmaceutical companies?
Yes. Dr. Kalla received a total of $2,626 from 25 companies across 37 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kalla's costs compare to other medical oncologys in Abilene?
Dr. Kalla's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kalla) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Abilene
Browse medical oncologys in Abilene ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology